Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 21, 2026, 8:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 2,840 matching trials from the live ClinicalTrials.gov search.
Not listed No phase listed Observational

Breast Cancer Liquid Biopsy Trial

NCT04962529
Conditions
Breast Cancer, Cancer
Interventions
Blood Draw
Procedure
Lead sponsor
Anthony Magliocco
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Hollywood, Florida • Ocala, Florida • Orlando, Florida + 4 more
Conditions
Metastatic Melanoma
Interventions
Olaparib, Pembrolizumab
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
San Francisco, California • Houston, Texas
Conditions
Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions
AQ4N
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Oxaliplatin, Trastuzumab
Drug
Lead sponsor
Hoosier Cancer Research Network
Other
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
Galesburg, Illinois • Bloomington, Indiana • Elkhart, Indiana + 6 more
Conditions
Metastatic ER+ Her2- Breast Cancer, Postmenopausal
Interventions
Exemestane, Abiraterone acetate + Prednisone/ Prednisolone + Exemestane, Abiraterone acetate + Prednisone or Prednisolone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
24
States / cities
Muscle Shoals, Alabama • Fresno, California • Los Angeles, California + 21 more
Conditions
Breast Cancer
Interventions
Zometa(drug)
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Cancer, Solid Tumor, Cancer of Skin
Interventions
2141 V-11
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Pemetrexed, Gemcitabine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
6
States / cities
Aurora, Colorado • Plantation, Florida • Morrisville, North Carolina + 3 more
Conditions
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites, Malignant Neoplasms of Independent (Primary) Multiple Sites, Malignant Neoplasms of Lip Oral Cavity and Pharynx, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Mesothelial and Soft Tissue, Malignant Neoplasms of Respiratory and Intrathoracic Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands, Malignant Neoplasms of Urinary Tract
Interventions
Pembrolizumab, Clostridium Novyi-NT, Doxycycline
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Conditions
Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer, Breast Cancer
Interventions
TAS2940
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
945 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Breast Cancer
Interventions
bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation
Biological · Drug
Lead sponsor
Premiere Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
peripheral blood progenitor cells carrying MDR1
Genetic
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Breast Cancer, Bone Metastases
Interventions
Skeletal Scintigraphy, Radiography, CT Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Houston, Texas
Conditions
Shared Decision Making
Interventions
Intervention-specific Carevive questionnaire, Standard of Care questionnaire
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Pancreatic Cancer
Interventions
Radiotherapy, MEDI4736, Tremelimumab
Radiation · Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Conditions
Breast Neoplasms
Interventions
Enzastaurin Hydrochloride
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Newark, Delaware • Indianapolis, Indiana • South Bend, Indiana + 1 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
aldesleukin, recombinant interferon alfa, sargramostim
Biological
Lead sponsor
Cancer Treatment Centers of America
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
1
States / cities
Zion, Illinois
Conditions
Breast Cancer
Interventions
trastuzumab, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
immunoenzyme technique, laboratory biomarker analysis, medical chart review
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Breast Cancer, Breast Cancer Stage IV, HER2-negative Breast Cancer, Solid Carcinoma, MEK1 Gene Mutation, MEK2 Gene Mutation, Metastatic Breast Cancer
Interventions
Mirdametinib, Fulvestrant
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Middletown, New Jersey • Commack, New York • Harrison, New York + 1 more
Conditions
Metastatic Breast Cancer
Interventions
Pegylated liposomal doxorubicin, Carboplatin, trastuzumab
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 51 more